Trials / Unknown
UnknownNCT02482272
Compare Continuing Lamivudine Plus Adefovir or Adefovir Versus Switching to Entecavir Plus Adefovir in Patients With LAM-resistant Chronic Hepatitis B
Efficacy and Safety of Continuing Lamivudine Plus Adefovir or Adefovir Versus Switching to Entecavir Plus Adefovir in Patients With Chronic Hepatitis B Who Have Resistant Mutants to Lamivudine and Show Suboptimal Response to Combination of Lamivudine Plus Adefovir or Adefovir Monotherapy
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- Sponsor
- Asan Medical Center · Academic / Other
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare efficacy and safety of continuing Lamivudine plus Adefovir or Adefovir versus switching to Entecavir plus Adefovir in patients with LAM-resistant chronic hepatitis B who have suboptimal response to Lamivudine plus Adefovir or Adefovir
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lamivudine | Lamivudine 100mg/day orally |
| DRUG | Adefovir | Adefovir 10mg/day orally |
| DRUG | Entecavir | Entecavir 1mg/day orally |
Timeline
- Start date
- 2015-05-01
- Primary completion
- 2017-01-01
- Completion
- 2017-05-01
- First posted
- 2015-06-26
- Last updated
- 2015-12-30
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02482272. Inclusion in this directory is not an endorsement.